| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sirolimus | 11 | 2015 | 831 | 0.970 |
Why?
|
| TOR Serine-Threonine Kinases | 13 | 2017 | 1563 | 0.750 |
Why?
|
| Proto-Oncogene Proteins c-akt | 9 | 2019 | 2069 | 0.630 |
Why?
|
| Breast Neoplasms | 19 | 2023 | 16215 | 0.520 |
Why?
|
| Phosphatidylinositol 3-Kinases | 7 | 2014 | 1710 | 0.490 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2021 | 9042 | 0.450 |
Why?
|
| Proteomics | 1 | 2021 | 1427 | 0.440 |
Why?
|
| Transcriptome | 1 | 2021 | 1963 | 0.400 |
Why?
|
| Genomics | 2 | 2021 | 2835 | 0.370 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 4 | 2021 | 529 | 0.350 |
Why?
|
| Triple Negative Breast Neoplasms | 5 | 2021 | 1386 | 0.340 |
Why?
|
| Signal Transduction | 12 | 2014 | 12103 | 0.330 |
Why?
|
| Protein Kinases | 4 | 2009 | 902 | 0.310 |
Why?
|
| Antigens, Neoplasm | 2 | 2006 | 1580 | 0.300 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 2 | 2022 | 525 | 0.300 |
Why?
|
| PTEN Phosphohydrolase | 4 | 2021 | 1012 | 0.290 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 3 | 2019 | 153 | 0.280 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2009 | 550 | 0.260 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2021 | 5408 | 0.250 |
Why?
|
| Xenograft Model Antitumor Assays | 9 | 2024 | 3917 | 0.230 |
Why?
|
| Barium Sulfate | 1 | 2002 | 41 | 0.210 |
Why?
|
| Colonic Diseases, Functional | 1 | 2002 | 19 | 0.210 |
Why?
|
| Protein Kinase Inhibitors | 6 | 2021 | 4961 | 0.210 |
Why?
|
| Enema | 1 | 2002 | 48 | 0.210 |
Why?
|
| Mice, Nude | 9 | 2022 | 4329 | 0.210 |
Why?
|
| Stearoyl-CoA Desaturase | 2 | 2012 | 20 | 0.200 |
Why?
|
| Cell Proliferation | 10 | 2021 | 7238 | 0.200 |
Why?
|
| Gene Expression Profiling | 3 | 2021 | 5149 | 0.190 |
Why?
|
| Peritoneal Neoplasms | 1 | 2008 | 859 | 0.190 |
Why?
|
| Oxadiazoles | 1 | 2021 | 60 | 0.190 |
Why?
|
| Esophageal Neoplasms | 2 | 2006 | 3240 | 0.190 |
Why?
|
| Neurofibromin 1 | 1 | 2021 | 84 | 0.180 |
Why?
|
| B7 Antigens | 1 | 2021 | 84 | 0.180 |
Why?
|
| Acute-Phase Reaction | 1 | 2000 | 24 | 0.170 |
Why?
|
| Antibodies, Bispecific | 1 | 2024 | 282 | 0.170 |
Why?
|
| Cation Transport Proteins | 1 | 2021 | 170 | 0.170 |
Why?
|
| Oxidative Phosphorylation | 1 | 2021 | 271 | 0.170 |
Why?
|
| Antibiotics, Antineoplastic | 3 | 2013 | 742 | 0.170 |
Why?
|
| Hernia, Inguinal | 1 | 2000 | 51 | 0.170 |
Why?
|
| Cell Line, Tumor | 14 | 2021 | 14849 | 0.160 |
Why?
|
| Antineoplastic Agents | 5 | 2021 | 14617 | 0.160 |
Why?
|
| Anilides | 1 | 2021 | 295 | 0.160 |
Why?
|
| Carrier Proteins | 1 | 2007 | 2098 | 0.160 |
Why?
|
| Colon | 1 | 2002 | 659 | 0.160 |
Why?
|
| Metabolome | 1 | 2021 | 355 | 0.160 |
Why?
|
| Benzimidazoles | 1 | 2022 | 437 | 0.160 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2021 | 3658 | 0.160 |
Why?
|
| RNA, Neoplasm | 1 | 2021 | 805 | 0.150 |
Why?
|
| Female | 32 | 2023 | 148940 | 0.150 |
Why?
|
| Cell Cycle Proteins | 3 | 2021 | 2115 | 0.150 |
Why?
|
| Phosphorylation | 7 | 2015 | 4942 | 0.150 |
Why?
|
| Teaching | 1 | 1999 | 250 | 0.150 |
Why?
|
| Accidents, Aviation | 1 | 1997 | 7 | 0.150 |
Why?
|
| Traumatology | 1 | 1997 | 26 | 0.140 |
Why?
|
| Receptor, ErbB-2 | 3 | 2024 | 2651 | 0.140 |
Why?
|
| Disaster Planning | 1 | 1997 | 69 | 0.140 |
Why?
|
| Humans | 40 | 2024 | 270740 | 0.140 |
Why?
|
| Multiple Trauma | 1 | 1997 | 77 | 0.140 |
Why?
|
| Evolution, Molecular | 1 | 2021 | 867 | 0.140 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 1997 | 75 | 0.140 |
Why?
|
| Neoplasms | 5 | 2015 | 15927 | 0.140 |
Why?
|
| Cytoplasm | 2 | 2009 | 702 | 0.130 |
Why?
|
| Contrast Media | 1 | 2002 | 1499 | 0.130 |
Why?
|
| Respiratory Function Tests | 1 | 1997 | 354 | 0.130 |
Why?
|
| Piperidines | 1 | 2021 | 1100 | 0.130 |
Why?
|
| Blotting, Western | 5 | 2011 | 3584 | 0.130 |
Why?
|
| Hydrazines | 1 | 2017 | 213 | 0.130 |
Why?
|
| Phthalazines | 1 | 2017 | 262 | 0.130 |
Why?
|
| Mutation | 5 | 2021 | 15912 | 0.130 |
Why?
|
| Mice | 14 | 2024 | 35600 | 0.130 |
Why?
|
| BRCA2 Protein | 1 | 2017 | 380 | 0.130 |
Why?
|
| DNA, Neoplasm | 1 | 2021 | 1958 | 0.130 |
Why?
|
| Animals | 18 | 2024 | 61956 | 0.120 |
Why?
|
| Developing Countries | 1 | 1997 | 349 | 0.120 |
Why?
|
| Paclitaxel | 4 | 2015 | 2101 | 0.120 |
Why?
|
| Interleukin-10 | 1 | 1997 | 483 | 0.120 |
Why?
|
| Pancreatitis | 1 | 1997 | 295 | 0.120 |
Why?
|
| Benzoxazoles | 1 | 2014 | 40 | 0.120 |
Why?
|
| BRCA1 Protein | 1 | 2017 | 528 | 0.120 |
Why?
|
| Pyridines | 1 | 2021 | 1313 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2022 | 16689 | 0.110 |
Why?
|
| Membrane Proteins | 1 | 2004 | 2928 | 0.110 |
Why?
|
| Heterografts | 1 | 2015 | 738 | 0.110 |
Why?
|
| Triazoles | 1 | 2017 | 627 | 0.110 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2012 | 64 | 0.100 |
Why?
|
| Emergency Medical Services | 1 | 1997 | 470 | 0.100 |
Why?
|
| Receptors, Estrogen | 3 | 2015 | 2170 | 0.100 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2021 | 2617 | 0.100 |
Why?
|
| Biomarkers, Tumor | 4 | 2021 | 10708 | 0.090 |
Why?
|
| Liver Neoplasms | 1 | 2008 | 4821 | 0.090 |
Why?
|
| Thyroid Neoplasms | 1 | 2022 | 1894 | 0.090 |
Why?
|
| Protein Biosynthesis | 2 | 2012 | 1028 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2021 | 5056 | 0.090 |
Why?
|
| Proteome | 1 | 2014 | 571 | 0.090 |
Why?
|
| MCF-7 Cells | 3 | 2017 | 547 | 0.090 |
Why?
|
| Receptors, Progesterone | 2 | 2012 | 1604 | 0.090 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2015 | 1002 | 0.080 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2009 | 230 | 0.080 |
Why?
|
| Neoplasm Proteins | 1 | 2021 | 3345 | 0.080 |
Why?
|
| Leucine | 1 | 2011 | 380 | 0.080 |
Why?
|
| Y-Box-Binding Protein 1 | 1 | 2009 | 44 | 0.080 |
Why?
|
| Adult | 12 | 2019 | 82040 | 0.080 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2009 | 122 | 0.080 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2009 | 135 | 0.080 |
Why?
|
| Eukaryotic Initiation Factor-4E | 1 | 2008 | 95 | 0.080 |
Why?
|
| Internship and Residency | 1 | 1999 | 1452 | 0.080 |
Why?
|
| Immunohistochemistry | 3 | 2019 | 7655 | 0.080 |
Why?
|
| Rapamycin-Insensitive Companion of mTOR Protein | 1 | 2007 | 31 | 0.070 |
Why?
|
| Pyrimidines | 2 | 2023 | 3669 | 0.070 |
Why?
|
| Transfection | 2 | 2015 | 3117 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 3 | 2022 | 2454 | 0.070 |
Why?
|
| Aged | 10 | 2019 | 73333 | 0.070 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2007 | 603 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2022 | 382 | 0.070 |
Why?
|
| B7-H1 Antigen | 1 | 2014 | 1089 | 0.070 |
Why?
|
| Apoptosis | 5 | 2021 | 7757 | 0.070 |
Why?
|
| Isoenzymes | 1 | 2009 | 648 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 2 | 2014 | 2399 | 0.070 |
Why?
|
| Middle Aged | 11 | 2019 | 90352 | 0.070 |
Why?
|
| Survival Analysis | 2 | 2009 | 9292 | 0.070 |
Why?
|
| Colorectal Neoplasms | 1 | 2022 | 3707 | 0.070 |
Why?
|
| Phosphoproteins | 2 | 2008 | 1138 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 1 | 2008 | 1189 | 0.070 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2009 | 694 | 0.070 |
Why?
|
| Carcinoid Tumor | 1 | 2008 | 282 | 0.060 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2012 | 743 | 0.060 |
Why?
|
| Lung Neoplasms | 1 | 2008 | 12033 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 10400 | 0.060 |
Why?
|
| RNA, Small Interfering | 2 | 2010 | 2196 | 0.060 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2008 | 1470 | 0.060 |
Why?
|
| Tumor Burden | 3 | 2015 | 2033 | 0.060 |
Why?
|
| Neoadjuvant Therapy | 2 | 2015 | 5231 | 0.060 |
Why?
|
| RNA | 1 | 2009 | 1063 | 0.060 |
Why?
|
| Drug Synergism | 2 | 2021 | 1356 | 0.060 |
Why?
|
| Prognosis | 3 | 2021 | 22505 | 0.060 |
Why?
|
| Time Factors | 3 | 2015 | 13006 | 0.060 |
Why?
|
| Disease Models, Animal | 3 | 2023 | 7381 | 0.060 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2023 | 95 | 0.050 |
Why?
|
| Antibody Formation | 1 | 2004 | 386 | 0.050 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2023 | 153 | 0.050 |
Why?
|
| Spasm | 1 | 2002 | 58 | 0.050 |
Why?
|
| Appendix | 1 | 2002 | 45 | 0.050 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2023 | 185 | 0.050 |
Why?
|
| Ileum | 1 | 2002 | 167 | 0.050 |
Why?
|
| Neuroendocrine Tumors | 1 | 2008 | 656 | 0.050 |
Why?
|
| HCT116 Cells | 1 | 2022 | 354 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 3844 | 0.050 |
Why?
|
| Testis | 1 | 2004 | 620 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2009 | 5101 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 2 | 2015 | 1322 | 0.050 |
Why?
|
| Aged, 80 and over | 4 | 2015 | 30998 | 0.050 |
Why?
|
| Everolimus | 2 | 2014 | 436 | 0.040 |
Why?
|
| Mathematical Computing | 1 | 1999 | 23 | 0.040 |
Why?
|
| Transplantation, Heterologous | 2 | 2012 | 1054 | 0.040 |
Why?
|
| Pyrroles | 1 | 2023 | 588 | 0.040 |
Why?
|
| Male | 8 | 2015 | 128315 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 2021 | 5759 | 0.040 |
Why?
|
| Mitosis | 1 | 2021 | 681 | 0.040 |
Why?
|
| Professional Competence | 1 | 1999 | 139 | 0.040 |
Why?
|
| Drug Administration Schedule | 2 | 2015 | 3530 | 0.040 |
Why?
|
| Cancer Vaccines | 1 | 2004 | 754 | 0.040 |
Why?
|
| Acrylonitrile | 1 | 2017 | 9 | 0.040 |
Why?
|
| Radiography | 1 | 2002 | 1986 | 0.040 |
Why?
|
| Turkey | 1 | 1997 | 66 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2022 | 885 | 0.040 |
Why?
|
| Rural Health | 1 | 1997 | 54 | 0.040 |
Why?
|
| Ketones | 1 | 2017 | 57 | 0.040 |
Why?
|
| Furans | 1 | 2017 | 102 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2019 | 352 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2000 | 558 | 0.030 |
Why?
|
| Aniline Compounds | 1 | 2017 | 206 | 0.030 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 5315 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 2345 | 0.030 |
Why?
|
| Neoplasm Staging | 3 | 2019 | 14012 | 0.030 |
Why?
|
| Health Services Research | 1 | 1997 | 237 | 0.030 |
Why?
|
| Snail Family Transcription Factors | 1 | 2015 | 120 | 0.030 |
Why?
|
| Triage | 1 | 1997 | 255 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2000 | 1050 | 0.030 |
Why?
|
| Enzyme Activation | 2 | 2009 | 1810 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2023 | 1546 | 0.030 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2015 | 167 | 0.030 |
Why?
|
| Allosteric Regulation | 1 | 2014 | 71 | 0.030 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2014 | 69 | 0.030 |
Why?
|
| Epirubicin | 1 | 2014 | 159 | 0.030 |
Why?
|
| Catalytic Domain | 1 | 2014 | 305 | 0.030 |
Why?
|
| Pyrimidinones | 1 | 2015 | 318 | 0.030 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2014 | 274 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2015 | 469 | 0.030 |
Why?
|
| Pyridones | 1 | 2015 | 360 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2017 | 520 | 0.030 |
Why?
|
| Drug Eruptions | 1 | 2015 | 271 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 3409 | 0.030 |
Why?
|
| Oncogene Protein v-akt | 1 | 2012 | 101 | 0.030 |
Why?
|
| Multiprotein Complexes | 1 | 2014 | 385 | 0.030 |
Why?
|
| Drug Design | 1 | 2014 | 372 | 0.030 |
Why?
|
| Hyperglycemia | 1 | 2015 | 337 | 0.030 |
Why?
|
| Cadherins | 1 | 2015 | 657 | 0.030 |
Why?
|
| Models, Biological | 2 | 2012 | 3194 | 0.030 |
Why?
|
| Research Design | 1 | 1999 | 1569 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2015 | 10265 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2017 | 1101 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2006 | 3557 | 0.020 |
Why?
|
| Acute Disease | 1 | 1997 | 2493 | 0.020 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2014 | 236 | 0.020 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2015 | 617 | 0.020 |
Why?
|
| Lung Diseases | 1 | 1997 | 755 | 0.020 |
Why?
|
| RNA Interference | 1 | 2015 | 1388 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 1076 | 0.020 |
Why?
|
| Treatment Outcome | 3 | 2019 | 33737 | 0.020 |
Why?
|
| Neutropenia | 1 | 2015 | 1006 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2014 | 757 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2015 | 1418 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2012 | 503 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2017 | 3145 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2015 | 1125 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 2359 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 2010 | 726 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2012 | 1697 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2010 | 6390 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2014 | 1990 | 0.020 |
Why?
|
| Fatigue | 1 | 2015 | 1275 | 0.020 |
Why?
|
| Nucleotides | 1 | 2009 | 174 | 0.020 |
Why?
|
| DNA Primers | 1 | 2010 | 1496 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2012 | 1823 | 0.020 |
Why?
|
| Biomarkers | 1 | 2019 | 5051 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 4000 | 0.020 |
Why?
|
| Octreotide | 1 | 2008 | 131 | 0.020 |
Why?
|
| Child | 2 | 2000 | 30559 | 0.020 |
Why?
|
| Transgenes | 1 | 2009 | 576 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2014 | 3245 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 4328 | 0.020 |
Why?
|
| Adolescent | 2 | 2013 | 32767 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 4372 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 3476 | 0.010 |
Why?
|
| Base Sequence | 1 | 2010 | 5437 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 6256 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 2471 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2015 | 2887 | 0.010 |
Why?
|
| Protein Binding | 1 | 2009 | 3485 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2015 | 5438 | 0.010 |
Why?
|
| DNA | 1 | 2009 | 3050 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2008 | 5694 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2009 | 3438 | 0.010 |
Why?
|
| Young Adult | 1 | 2013 | 22251 | 0.010 |
Why?
|
| Survival Rate | 1 | 2008 | 12541 | 0.010 |
Why?
|